Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
BACKGROUND It is well established that depressive disorders are more prevalent in women ; however gender differences in the pharmacological response to antidepressants are not a consistent finding in all reports . It is considered that this discrepancy can be explained by the fact that in most clinical trials drug use for comparative purpose s is not completely different . In this study gender differences in antidepressant response with citalopram ( CTP ) , a selective serotonin reuptake inhibitor and reboxetine ( RBX ) , a selective noradrenaline reuptake inhibitor were evaluated in a group of young men and premenopausal women . METHOD Eighty-six depressed patients 18 to 40 years old participated in an 8-week double-blind clinical trial . Subjects were divided in four groups according to sex and treatment assignation : females treated with CTP ( n = 25 ) or RBX ( n = 23 ) , and males treated with CTP ( n = 19 ) or RBX ( n = 19 ) . Response was determined using HDRS and BDI . RESULTS ANOVA analysis considering change in HDRS scores from baseline to last evaluation found a significant interaction between gender and type of treatment . Females treated with CTP showed a significantly greater response than females treated with RBX , while in men no differences were observed for both drugs . LIMITATIONS Replication using larger sample size and longer treatment periods is required . CONCLUSIONS These results support previous findings which show that premenopausal women respond better than men to serotonergic antidepressants . They also support that a plausible interaction between gonadal hormones and serotonin may explain gender differences in antidepressant response
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .